Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Anup Radhakrishnan | Interim CEO, CFO, Secretary & COO | 667.1k | -- | 1980 |
| Dr. Crystal L. Mackall M.D. | Co-Founder & Scientific Advisory Board Chair | 160k | -- | 1961 |
| Dr. Robbie Majzner M.D. | Co-Founder & Scientific Advisory Board Member | -- | -- | -- |
| Ms. Nancy Goodman J.D. | Founder | -- | -- | -- |
| Dr. Louai Labanieh | Founder | -- | -- | -- |
| Ms. Halley E. Gilbert Esq., J.D. | Chief Legal Officer | -- | -- | 1970 |
| Ms. Kari E. Leetch | Chief People Officer | -- | -- | -- |
| Mr. Erik Poulsen M.S. | Head of Regulatory Affairs | -- | -- | -- |
CARGO Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 167
Description
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is based in San Mateo, California.
Corporate Governance
Upcoming Events
May 12, 2025 at 8:05 PM UTC - May 17, 2025 at 8:05 PM UTC
CARGO Therapeutics, Inc. Earnings Date